BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Affinium Pharmaceuticals Awarded US$4.8 Million Biodefense Research Contract By United States Department Of Defense/DTRA


1/4/2007 12:23:45 PM

TORONTO, Jan. 4 /PRNewswire/ - Affinium Pharmaceuticals, Inc., has executed a two-year US$4.8 million research contract with the Defense Threat Reduction Agency (DTRA), an agency of the United States Department of Defense (DoD). The contract will fund preclinical studies of selected compounds from Affinium's fatty acid biosynthesis inhibitor portfolio that have demonstrated potential as therapeutics for the treatment of diseases caused by serious pathogens including Francisella tularensis, a potential biological warfare and bioterrorism agent. This DTRA contract builds on Affinium's previous successful research into the inhibition of Francisella tularensis conducted with the US National Institute of Allergy and Infectious Diseases.

"Our partnership with DTRA and the DoD serves as validation of Affinium's portfolio of potent oral antibacterial therapeutics," said Nachum Kaplan Vice President Microbiology of Affinium. "We believe that through this contract we will continue to demonstrate the high efficacy and desired pharmacokinetics of this new class of antibiotics."

"We are excited that DTRA has partnered with Affinium and shares our view that the inhibition of the fatty acid biosynthesis pathway presents a unique opportunity to develop safe and potent oral antibiotics which can be administered to patients both inside and outside of the hospital environment," said Owen Roberts, Chief Financial Officer of Affinium.

Under the contract, Affinium will investigate the properties of a select group of its proprietary compounds. Following these initial investigations, Affinium and its partners will conduct microdosing studies to characterize the compounds' human pharmacokinetic properties and select a lead development candidate to undergo IND-enabling preclinical development as an oral tularemia therapeutic.

About Affinium Pharmaceuticals, Inc.

Affinium Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines stemming from the bacterial fatty acid synthesis (FAS) II pathway. Affinium's lead clinical development compound is a highly potent small molecule antibiotic for both oral and IV treatment of staphylococcal infections including drug-resistant MRSA. This development candidate is scheduled for Phase I clinical trials in the second half of 2007. Additionally, Affinium utilizes its unique proprietary compounds and its knowledge of fatty acid biosynthesis enzymes to develop additional novel antibiotics to address a variety of therapeutic needs. For more information about Affinium please contact Owen Roberts, CFO at 416-645-6613 or oroberts@afnm.com.

Affinium Pharmaceuticals

CONTACT: Executive Contact: Owen G. Roberts, CFO, Phone: (416) 645-6613,Email: oroberts@afnm.com, www.afnm.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES